Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:1793  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 


 
   Table of Contents     
ORIGINAL ARTICLE  
Year : 2022  |  Volume : 14  |  Issue : 3  |  Page : 99-105
A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait


1 Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait
2 Department of Internal Medicine, Al-Azhar University, Cairo, Egypt
3 Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait; Department of Gastroenterology, Lancashire Teaching Hospitals NHS Trust, Chorley, UK

Click here for correspondence address and email

Date of Submission20-Jan-2022
Date of Decision01-Mar-2022
Date of Acceptance09-Mar-2022
Date of Web Publication26-Aug-2022
 

   Abstract 

Introduction: Helicobacter pylori-induced chronic infection is associated with peptic ulcer, chronic gastritis, gastric cancer, and increasing antibiotic resistance. We aimed to evaluate the efficacy of clarithromycin-based triple therapy and non-bismuth based quadruple therapy for eradicating H. pylori in patients with chronic gastritis in Kuwait. Methods: We enrolled a total of 603 treatment-naive dyspeptic patients with gastric biopsy-proven chronic gastritis secondary to H. pylori in a prospective, open-label, randomized study. Patients were randomized into two groups: a group received the standard triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days and a group received quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days. All patients were tested for the eradication of H. pylori by carbon-13 urea breath test 1 month after eradication therapy. Results: The overall eradication rate was 63.2%. The eradication rates in intention-to-treat (ITT) and per protocol (PP) population were 58.4% and 64.6%, respectively, in triple therapy group. In the quadruple therapy group, the eradication rates in ITT and PP population were 68.0% and 78.5%, respectively, with a statistically significant higher eradication rate in patients treated by quadruple therapy than the triple therapy (P < 0.01). Multivariate logistic regression analysis revealed that treatment regimen was the only significant predictor for successful H. pylori eradication. The most common adverse events were abnormal taste, headache, dizziness, and abdominal pain. Conclusion: Non-bismuth based quadruple therapy is more effective than standard clarithromycin-based triple therapy for eradicating H. pylori in patients with chronic gastritis.
ClinicalTrials.gov Identifier: NCT04617613

Keywords: Amoxicillin, clarithromycin, Helicobacter pylori, metronidazole, omeprazole, quadruple therapy, triple therapy

How to cite this article:
Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. J Global Infect Dis 2022;14:99-105

How to cite this URL:
Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. J Global Infect Dis [serial online] 2022 [cited 2022 Oct 2];14:99-105. Available from: https://www.jgid.org/text.asp?2022/14/3/99/354695

Ahmad Alfadhli, Mohamed Alboraie. The first two authors contributed equally to this work and share first authorship.



   Introduction Top


Helicobacter pylori infection is a common public health problem that affects 7%–87% of adults.[1],[2] Its prevalence varies significantly among countries and population groups within the same country due to a strong correlation with factors including geography, culture, age, and socioeconomic status.[3] H. pylori infects approximately 50% of the worldwide adult population and is more common in developing countries.[4] The increased prevalence of H. pylori in developing countries is attributed to polluted drinking water, basic hygiene, poor diet, and overcrowded living conditions. The prevalence of H. pylori in Kuwait is estimated to be 42.6% among Kuwaitis and 57.6% among expatriates (non-Kuwaitis). In addition, males tend to be affected more (51.3%) than their female counterparts (48.6%).[5]

H. pylori infection is associated with a number of digestive diseases including chronic gastritis, peptic ulcer disease, and gastric malignancies such as mucosa-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma.[6] However, eradication of the organism effectively prevents relapses of gastroduodenal ulcers and associated gastric malignancies.[7] In addition, the latest Maastricht V Consensus has reconfirmed the strong recommendation for H. pylori eradication in infected patients with peptic ulcer and MALT lymphoma and for those with functional dyspepsia.[8],[9],[10]

Treatment strategies for the eradication of H. pylori continue to evolve and is still a major challenge. The standard triple therapy for H. pylori utilizes proton-pump inhibitors (PPIs) in combination with several antibiotics such as clarithromycin plus amoxicillin or metronidazole. The triple therapy has been considered the preferred first-line treatment for H. pylori infection until recently.[11] Previous studies suggested that the efficacy of standard triple therapy for H. pylori eradication in Kuwaitis was suboptimal.[5] Hence, the bacterium's resistance to clarithromycin is increasing rapidly. However, the eradication rate of standard triple therapy has declined to <80% in most countries worldwide due to increasing resistance rate to antibiotics.[12],[13],[14],[15] The Kyoto Consensus Report on H. pylori recommends that, within any region, only regimens which reliably produce eradication rates of ≥90% in that population should be used.[16] Therefore, continued use of standard triple therapy has recently been interrogated, and alternative approaches with minimal bacterial resistance have been recommended. A good alternative in areas with high clarithromycin resistance could be nitazoxanide–levofloxacin-containing triple therapy that showed eradication rates of ≥90% in a recent study.[17]

Several attempts to implement new first-line treatments resurfaced. Trials of increasing the duration of triple therapy, thus prolonging exposure to antibiotics, were conducted but achieved controversial results and have not generally resulted in noteworthy benefits.[18],[19]

Sequential treatment which involves a simple dual regimen including a PPI plus amoxicillin for the first 5 days followed by a triple regimen including a PPI, clarithromycin, and tinidazole for the following 5 days was another promising approach. Several randomized clinical trials have concluded that a sequential regimen is more effective than standard triple therapy.[20],[21],[22],[23],[24] Therefore, sequential therapy was proposed to be an alternative to standard triple therapy for the eradication of H. pylori.[25] However, a recently updated meta-analysis performed by a Cochrane collaboration group found that the results obtained with the sequential regimen were heterogeneous and the sequential therapy cannot be presented as a valid alternative to standard triple therapy. Furthermore, neither sequential therapy nor standard triple therapy regimens achieved optimal efficacy (≥90% eradication rate).[26]

From this perspective, the triple combination of clarithromycin plus amoxicillin and metronidazole with a PPI (without bismuth) has previously been examined as a nonsequential regimen, which proved its efficacy. Thus, the concept of a non-bismuth quadruple regimen (or concomitant treatment) has recently emerged as an effective regimen for eradicating H. pylori.[27],[28],[29] Traditional standard triple therapy (PPI, clarithromycin, and amoxicillin) can easily be converted to concomitant therapy by adding 500 mg of metronidazole or tinidazole twice daily.[30] A meta-analysis of 19 studies revealed a mean H. pylori cure rate of about 90% for concomitant therapy. A trend toward better outcomes with longer treatment durations with the concomitant regimen has been observed.[31] Experience with the quadruple therapy in patients with metronidazole-resistant strains is still very limited. Although susceptibility guided treatment would be the best first-line option, it is clinically applicable in different parts of the world. Guidelines still recommend empirical approach for 14-day treatment for the eradication of H. pylori to provide simplicity for clinicians.[29] Evidence supporting these conclusions is insufficient because no studies with an appropriate design have been performed. With these considerations in mind, we designed the present randomized controlled trial to compare the efficacy of clarithromycin-based triple therapy (omeprazole, amoxicillin, and clarithromycin) and no-nbismuth based quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for the eradication of H. pylori in treatment-naïve patients with H. pylori-related chronic gastritis in Kuwait.


   Methods Top


We followed the Consolidated Standards of Reporting Trials statement guidelines[32] when reporting this manuscript. This study was approved by the Ethics Committee of the Ministry of Health in Kuwait and all enrolled patients signed informed consent to participate in the study.

Study design, study setting, and study participants

We conducted a prospective, open-label, randomized controlled trial in the gastroenterology outpatient clinics of Haya Al-Habeeb Gastroenterology Center, Mubarak AL-Kabeer Hospital in Kuwait. We included patients meeting the following criteria: (1) male and female dyspeptic subjects aged ≥18 years with any nationality; (2) patients with gastric biopsy-proven H. pylori-related chronic gastritis and no other abnormalities in the upper gastrointestinal tract upon endoscopy, and (3) patients who were naive to treatment for H. pylori infection.

We excluded cases in the following conditions: (1) pregnant or breastfeeding females, (2) patients who were previously treated for H. pylori infection, and (3) patients who received any antibiotics, bismuth, or acid-suppressant drugs within the last month.

Study treatments

Patients were randomized in a 1:1 ratio using a SAS-based computer-generated randomization scheme into two groups. The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.

Study assessments

For each eligible patient, we reported the following data: (1) demographic data including age, gender, and nationality; (2) the main patient's complaint; (3) the results of physical examination; (4) H. pylori eradication rate defined as negative 13-carbon urea breath test (13C-UBT) 1 month after treatment; and (5) the reported adverse events during the study period.

Study endpoints

The primary endpoint was the H. pylori eradication rate defined as the frequency of patients who have negative UBT (at least 1 month after treatment) in both treatment arms divided by the total number of patients (intention-to-treat [ITT]) or divided by those completed the treatment course (as per protocol [PP]). The secondary endpoints included compliance and adverse events defined as an event not present prior to exposure to the study medication or any event already present that worsens following exposure to study medication up to 2 months after study discontinuation.

Sample size

The sample size was calculated using power and sample size calculator (PS version 3.0.34). A dropout rate of 20% was considered, and the sample size was chosen to detect a 12% difference in proportions of participants who achieved H. pylori eradication in both treatment arms using the Chi-squared test assuming H. pylori eradication rate of 78% among standard triple therapy group versus 90% among quadruple therapy group. These calculations were made based on the assumption that study power is 95% and type I error probability is 0.05.

Statistical analysis

Data were summarized as frequencies and percentages for categorical variables. For continuous variables, data were summarized as mean and standard deviation if normally distributed or as median and interquartile ranges if not normally distributed. Comparison of quantitative variables was performed using the two-sample t-test or the MannWhitney U-test. Comparison of qualitative variables was carried out by the Chi-squared test. Multivariate logistic regression analyses were performed to identify factors affecting the eradication rate. A P value level smaller than 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS software version 25.0 (SPSS Inc., Chicago, IL, USA).


   Results Top


Characteristics of the study population

The present study included 603 patients. Of them, 303 patients with mean (± standard deviation [SD]) age of 44.4 (±15.4) were assigned to receive the standard triple therapy, and 300 patients with mean (SD) age of 42.4 (±13.4) were assigned to receive the quadruple therapy. [Figure 1] shows the flow diagram of the included patients throughout the study period. The characteristics of the study population are shown in [Table 1]. Male-to-female ratio was comparable in the two groups. There were no differences between the two groups with regard to age, gender, or nationalities (P > 0.05).
Figure 1: Flow chart of enrolled patients

Click here to view
Table 1: Baseline characteristics in the treated population

Click here to view


In the standard triple therapy group, abdominal pain, dyspepsia, nausea, and vomiting were the most common complaints (22.5%), followed by heartburn (15.9%). The same results were observed in the quadruple therapy group. Most of the patients were normal during the physical examination, and only four patients in each group had epigastric tenderness. The study population included 23 nationalities. The most common nationalities were Kuwaitis (31.2%), Egyptians (27.9%), Jordanians (7.8%), Indian (7.5%), and Syrian (6.6%) [Figure 2].
Figure 2: Nationality of included patients in the study

Click here to view


Safety analysis

Adverse events were described for 119 patients (39.3%) in the triple therapy group, while in the quadruple therapy group, the adverse events were described for 185 patients (61.7%). The most common adverse events were abnormal taste, headache, diarrhea, dizziness, and abdominal pain.

Efficacy analysis

The overall eradication rate was 63.2% (381/603). Regarding the triple therapy group, eradication rates as PP and ITT analysis were 64.6% and 58.4%, respectively, while in the quadruple therapy group, the eradication rates in ITT and PP were 68.0% and 78.5%, respectively [Table 2]. Pearson's Chi-Square test revealed a statistically significant higher eradication rate in patients treated with quadruple therapy than with the triple therapy (P < 0.01).
Table 2: Eradication rate in the per protocol and intention-to-treat populations

Click here to view


In the triple therapy group, the eradication rates in males and females were 67.4% and 62.0%, respectively. While in the quadruple therapy group, the eradication rates were 81.1% in males and 75.2% in females. In Kuwaitis patients, the eradication rate was 60.5% in the triple therapy group, while in the quadruple therapy group, the eradication rate was 77.0%. In non-Kuwaitis, the eradication rate was 66.8% in the triple therapy group, while in the quadruple therapy group, the eradication rate was 79.2%. In Egyptian patients, the eradication rate was 65.1% in the triple therapy group, while in the quadruple therapy group, the eradication rate was 86.7%. In non-Egyptian, the eradication rate was 64.7% in the triple therapy group, while in the quadruple therapy group, the eradication rate was 76% [Figure 3]. In both treatment groups, the number of patients with symptoms improvement was significantly increased throughout the study period as shown in [Figure 4]. Furthermore, in both treatment groups, the number of epigastric tenderness was significantly decreased throughout the study visits as shown in [Supplementary Figure 1].
Figure 3: Helicobacter pylori Eradication rates based on different baseline characteristics

Click here to view
Figure 4: Percentage of symptoms improvement after eradication therapy. Pearson Chi-Square test did not reveal any difference in the percentage of patients who had symptoms improvement between the two groups all over the study period (P > 0.05)

Click here to view



In both treatment groups, eradication rates were somewhat higher in males (67.4% and 81.1%) than in females (62.0% and 75.2%) and in non-Kuwaitis (66.8% and 79.2%) than in Kuwaitis (60.5% and 77.0%) [Supplementary Table 1]. In the quadruple group, the eradication rate in Egyptians was 86.7%, compared to 76.0% in non-Egyptians; the eradication rate in Africans was 82.1%, compared to 77.1% in Asians. In the standard triple group, the eradication rate in non-Arabs (71.4%) was higher than in Arabs (63.9%). However, in the multivariate logistic regression analysis, none of the above factors was a significant predictor of the eradication rate.




   Discussion Top


Many of antibiotic regimens have been evaluated for the treatment of H. pylori.[33],[34],[35],[36] However, there are limited data about the antibiotic resistance rates to guide the treatment of H. pylori.[37] The most common regimens are the clarithromycin-based triple therapy, the non-bismuth sequential or the concomitant quadruple therapy, and the bismuth-based quadruple therapies.[38] The choice of initial antibiotic regimen for the treatment of H. pylori should be supported by the presence of risk factors for macrolide resistance.[39] In patients with risk factors for macrolide resistance, clarithromycin-based therapy should be avoided. In the United States, it is assumed that clarithromycin resistance rates are more than 15%, leading to eradication rates with clarithromycin triple therapy <85%.[40] In Kuwait, there is no sufficient data about clarithromycin resistance.[41] Consequently, high eradication rate of clarithromycin-containing therapy cannot be guaranteed.

Therefore, we conducted our study to delineate the efficacy of two clarithromycin-containing regimens for eradicating H. pylori infection in patients with chronic gastritis in Kuwait. Most of the included patients were Kuwaitis (31.2%) and Egyptian (27.9%). The baseline and demographic characteristics were comparable between the two groups with no differences in age, gender, or nationalities (P > 0.05). These characters were comparable with the previously published articles by Alazmi et al.[42] The study population included 23 nationalities: Kuwaitis, Egyptians, Jordanians, Indian, Syrian, Canadian, Afghani, Ethiopian, Lebanese, and others. Differences in treatment outcomes between the studied nationalities may be explained by differences in baseline clarithromycin resistance, different socioeconomic and environmental factors, or because of the presence of multiple different strains of H. pylori. Epidemiological studies revealed that the occurrence of different strains of the bacteria varies between geographical areas and response to treatment varices due to variable efficacy of PPIs and resistance to antibiotics.[4]

Kyoto global consensus report confirmed that treatment regimen is considered effective when it achieves more than 90% eradication rate.[16] However, the eradication rates for the most commonly used regimens in clinical practice have fallen below 80%. This is generally because of poor compliance with medication and the rising rates of antibiotic resistance. [12],[15],[30],[14]

Our study reported an overall eradication rate of 63.18% in both groups with clarithromycin-containing therapy, which was less than the overall eradication rate of 77.5% in the previous report by Alboraie et al. in Kuwait, where the eradication rates were 64.6% in the 10 days triple therapy group and 78.5% in the bismuth quadruple therapy group as PP analysis.[43] Results of a recent meta-analysis by Gatta et al. showed that global eradication rates for the 14-day standard triple therapy range between 79.5% and 84.7%.[44]

We presented that the efficacy of 14-day clarithromycin-based triple therapy for eradicating H. pylori (63.2%) is lower than that reported earlier from Kuwait (68.6%),[4] although there was a single report indicating 0% resistance to clarithromycin among patients in Kuwait.[41] This discrepancy may be explained by the fact that the previous study was performed 13 years ago, and the macrolides resistance could be developed during this time interval.

The frequency of primary clarithromycin resistance to H. pylori strains is increasing worldwide. A meta-analysis of 31 studies revealed that the overall H. pylori antibiotic resistance rates were 17.2% for clarithromycin, 26.7% for metronidazole, 11.2% for amoxicillin, 16.2% for levofloxacin, 5.9% for tetracycline, and 1.4% for rifabutin. The prevalence rate of clarithromycin, metronidazole, and levofloxacin resistance significantly increased from Europe to Asia, America, and Africa.[45]

It is generally accepted that clinical factors influencing the eradication rate have been unclear. Several studies proposed the possibility that age was one of the main factors affecting the eradication rate among treatment groups.[46],[47],[48] In our study, the treatment group either triple or quadruple therapy was the only significant predictor for the eradication rate in a multivariate logistic regression analysis and there were no significance differences in the eradication rate regarding age, sex, or nationality. Studies with larger sample size are recommended for identifying other predictors of eradication rate in both regimens.

Limitations of our study are we did not evaluate the antibiotics resistance in our study which is recommended to be done in subsequent studies. No comparison was done with other antibiotics that may have higher eradication rates like levofloxacin and nitazoxanide.[17] On the other hand, we have many strength points including (1) large representative sample size and (2) it is the first comparative study to assess the efficacy and safety of standard tripe therapy versus the non-bismuth based quadruple therapy for the eradication of H. pylori in a large multinational patient population in Kuwait.


   Conclusion Top


Our study demonstrated the superiority of the 14-day non-bismuth based quadruple therapy over the clarithromycin-based triple therapy for H. pylori eradication. This is most likely due to an increasing rate of resistance to clarithromycin in Kuwait over the past 13 years, leading to reduced efficacy of the standard triple therapy. Further studies are recommended to identify local resistance to guide the choice of appropriate therapy.

Research quality and ethics statement

This study was approved by the Ethics Committee (Kuwait Ministry of health Ethics Committee Approval #2016-367). The authors followed applicable EQUATOR Network (http://www.equator-network.org/) guidelines during the conduct of this research project.

Acknowledgment

This work was supported by Abbott Laboratories GmbH.

Declaration for all articles: We also certify that none of the authors is a member of the Editorial board of the JGID.

Financial support and sponsorship

This study was supported by Abbott.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010;15 Suppl 1:1-6.  Back to cited text no. 1
    
2.
de Martel C, Parsonnet J. Helicobacter pylori infection and gender: A meta-analysis of population-based prevalence surveys. Dig Dis Sci 2006;51:2292-301.  Back to cited text no. 2
    
3.
Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.  Back to cited text no. 3
    
4.
Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299-304.  Back to cited text no. 4
    
5.
Alazmi WM, Siddique I, Alateeqi N, Al-Nakib B. Prevalence of Helicobacter pylori infection among new outpatients with dyspepsia in Kuwait. BMC Gastroenterol 2010;10:14.  Back to cited text no. 5
    
6.
Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, Mehrabani M, Hosseinzadeh H, et al. In vitro antibacterial activity of some Iranian medicinal plant extracts against Helicobacter pylori. Nat Prod Res 2011;25:1059-66.  Back to cited text no. 6
    
7.
Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection – The maastricht IV/florence consensus report. Gut 2012;61:646-64.  Back to cited text no. 7
    
8.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30.  Back to cited text no. 8
    
9.
Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma: Old and new insights. Ann Gastroenterol 2014;27:27-33.  Back to cited text no. 9
    
10.
Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: Resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-6.  Back to cited text no. 10
    
11.
Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J 2013;54:1-4.  Back to cited text no. 11
[PUBMED]  [Full text]  
12.
Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004;10:668-71.  Back to cited text no. 12
    
13.
Mégraud F. H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004;53:1374-84.  Back to cited text no. 13
    
14.
Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, et al. Sequential therapy versus triple therapy for the first line treatment of Helicobacter pylori in Korea: A nationwide randomized trial. Gut Liver 2016;10:556-61.  Back to cited text no. 14
    
15.
De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100.  Back to cited text no. 15
    
16.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.  Back to cited text no. 16
    
17.
Shehata MA, Talaat R, Soliman S, Elmesseri H, Soliman S, Abd-Elsalam S. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter 2017;22:e12395. [doi: 10.1111/hel. 12395].  Back to cited text no. 17
    
18.
Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9.  Back to cited text no. 18
    
19.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.  Back to cited text no. 19
    
20.
Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010-2.  Back to cited text no. 20
    
21.
Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis. Gut 2007;56:1353-7.  Back to cited text no. 21
    
22.
Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.  Back to cited text no. 22
    
23.
Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: A meta-analysis. J Clin Pharm Ther 2009;34:41-53.  Back to cited text no. 23
    
24.
Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.  Back to cited text no. 24
    
25.
Zullo A, Ridola L, Efrati C, Giorgio F, Nicolini G, Cannaviello C, et al. First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy. Ann Gastroenterol 2014;27:357-61.  Back to cited text no. 25
    
26.
Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016 Jun 28;2016(6):CD009034.  Back to cited text no. 26
    
27.
Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: A critical review. J Clin Gastroenterol 2010;44:313-25.  Back to cited text no. 27
    
28.
Vakil N. Helicobacter pylori treatment: Is sequential or quadruple therapy the answer? Rev Gastroenterol Disord 2008;8:77-82.  Back to cited text no. 28
    
29.
Gisbert JP, Calvet X. Review article: Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-17.  Back to cited text no. 29
    
30.
Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.  Back to cited text no. 30
    
31.
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.  Back to cited text no. 31
    
32.
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Med 2010;7:e1000251.  Back to cited text no. 32
    
33.
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73.  Back to cited text no. 33
    
34.
Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45-9.  Back to cited text no. 34
    
35.
Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.  Back to cited text no. 35
    
36.
Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment – A pilot study. Helicobacter 2012;17:374-81.  Back to cited text no. 36
    
37.
Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection – A continuing challenge from an old enemy. Biomark Res 2017;5:23.  Back to cited text no. 37
    
38.
Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest 2018;48:e12857.  Back to cited text no. 38
    
39.
Jallon JM, Risler Y, Iwatsubo M. Beef liver L-Glutamate dehydrogenase mechanism: Presteady state study of the catalytic reduction of 2.oxoglutarate by NADPH. Biochem Biophys Res Commun 1975;67:1527-36.  Back to cited text no. 39
    
40.
Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10:1088-94.  Back to cited text no. 40
    
41.
John Albert M, Al-Mekhaizeem K, Neil L, Dhar R, Dhar PM, Al-Ali M, et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther 2006;24:1359-66.  Back to cited text no. 41
    
42.
Alazmi WM, Buhaimed W, Al-Mekhaizeem K, Siddique I. Efficacy of standard triple therapy in the treatment of Helicobacter pylori infection: Experience from Kuwait. Dig Dis Sci 2010;55:3120-3.  Back to cited text no. 42
    
43.
Alboraie M, Saad M, Al-Ali J, Malik M, Asem N, Schmidt I, et al. Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait. Arab J Gastroenterol 2015;16:131-5.  Back to cited text no. 43
    
44.
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.  Back to cited text no. 44
    
45.
De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: A systematic review. J Gastrointestin Liver Dis 2010;19:409-14.  Back to cited text no. 45
    
46.
Neville PM, Everett S, Langworthy H, Tompkins D, Mapstone NP, Axon AT, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501.  Back to cited text no. 46
    
47.
Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: A randomized controlled trial (MACLOR study). Arch Intern Med 2002;162:153-60.  Back to cited text no. 47
    
48.
Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001;15:1023-9.  Back to cited text no. 48
    

Top
Correspondence Address:
Prof. Mohamed Alboraie
Department of Internal Medicine, Faculty of Medicine, Al-Azhar University, Nasr City 11884, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jgid.jgid_13_22

Rights and Permissions


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Methods
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1167    
    Printed20    
    Emailed0    
    PDF Downloaded176    
    Comments [Add]    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008